CIK: 0001777015
Total reported value
$969.6M
Reporting period: 2026-03-31 · Number of holdings: 90
Parkman Healthcare Partners LLC disclosed 90 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $969.6M and a quarterly turnover rate of 71.7%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "P"
Parkman Healthcare Partners LLC's disclosed holdings carry a Herfindahl concentration index of 0.021 — mathematically equivalent to about 47 equally-sized positions, well below its 90 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.95), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 46% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add XENE
+222.4% $22.0M
Add PTCT
+169.3% $17.2M
Trim MCK
-65.1% -$18.9M
Add SYK
+46.7% $13.8M
Trim BSX
-10.3% -$19.6M
Trim UPB
-5.7% -$15.6M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SYK | Stryker CORP | Stock-Healthcare | 5.24% | +1.71% | +46.74% | |
| 2 | DXCM | Dexcom INC | Stock-Healthcare | 4.47% | — | +17.42% | |
| 3 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 3.81% | +1.09% | +3.79% | |
| 4 | PODD | Insulet CORP | Stock-Healthcare | 3.39% | -0.42% | +11.15% | |
| 5 | LLY | Eli Lilly & Co | Stock-Healthcare | 3.28% | +3.28% | NEW | |
| 6 | PTCT | Ptc Therapeutics INC | Stock-Healthcare | 3.03% | +1.87% | +169.30% | |
| 7 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 2.98% | +2.32% | +222.36% | |
| 8 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.90% | -1.64% | -10.34% | |
| 9 | CVS | Cvs Health CORP | Stock-Healthcare | 2.87% | -0.53% | -13.97% | |
| 10 | RCUS | Arcus Biosciences INC | Stock-Other | 2.69% | — | +24.64% | |
| 11 | LIVN | LivaNova PLC | Stock-Other | 2.65% | — | -1.69% | |
| 12 | ZBH | Zimmer Biomet Holdings INC | Stock-Healthcare | 2.51% | +1.22% | +78.46% | |
| 13 | MBX | Mbx Biosciences INC | Stock-Other | 2.46% | — | -9.67% | |
| 14 | ANIP | Ani Pharmaceuticals INC | Stock-Other | 2.23% | +1.14% | +93.50% | |
| 15 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 2.17% | +1.02% | +57.05% | |
| 16 | QGEN | Qiagen N.V. | Stock-Healthcare | 2.06% | +2.06% | NEW | |
| 17 | NVST | Envista Holdings CORP | Stock-Healthcare | 1.86% | +1.86% | NEW | |
| 18 | EYPT | Eyepoint INC | Stock-Other | 1.80% | — | +24.52% | |
| 19 | ABBV | Abbvie INC | Stock-Healthcare | 1.68% | +1.68% | NEW | |
| 20 | BCRX | Biocryst Pharmaceuticals INC | Stock-Other | 1.68% | +1.01% | +89.78% | |
| 21 | IQV | Iqvia Holdings INC | Stock-Healthcare | 1.52% | +0.76% | +146.10% | |
| 22 | AGIO | Agios Pharmaceuticals INC | Stock-Other | 1.41% | +1.15% | +305.13% | |
| 23 | ILMN | Illumina INC | Stock-Healthcare | 1.40% | +1.40% | NEW | |
| 24 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.38% | — | +10.71% | |
| 25 | NBIX | Neurocrine Biosciences INC | Stock-Healthcare | 1.35% | — | -13.64% | |
| 26 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 1.29% | -1.32% | -61.04% | |
| 27 | ASMB | Assembly Biosciences INC | Stock-Other | 1.18% | — | +64.92% | |
| 28 | GPCR | Structure Therapeutics INC | Stock-Other | 1.15% | +0.79% | +321.99% | |
| 29 | MCK | Mckesson CORP | Stock-Healthcare | 1.13% | -1.71% | -65.13% | |
| 30 | STOK | Stoke Therapeutics INC | Stock-Other | 1.13% | — | -21.77% | |
| 31 | VRDN | Viridian Therapeutics INC | Stock-Other | 1.13% | -1.20% | -29.20% | |
| 32 | WAY | Waystar Holding CORP | Stock-Other | 1.10% | — | +20.06% | |
| 33 | MLYS | Mineralys Therapeutics INC | Stock-Other | 1.06% | -0.36% | -7.34% | |
| 34 | EWTX | Edgewise Therapeutics INC | Stock-Other | 1.05% | — | -24.52% | |
| 35 | XERS | Xeris Biopharma Holdings INC | Stock-Other | 1.03% | — | +1.75% | |
| 36 | THC | Tenet Healthcare CORP | Stock-Healthcare | 0.98% | — | -17.17% | |
| 37 | AORT | Artivion INC | Stock-Other | 0.95% | — | +15.25% | |
| 38 | NUVL | Nuvalent Inc-a | Stock-Other | 0.93% | — | -25.81% | |
| 39 | ATEC | Alphatec Holdings INC | Stock-Other | 0.92% | — | +197.19% | |
| 40 | ALNY | Alnylam Pharmaceuticals INC | Stock-Healthcare | 0.92% | -0.89% | -43.58% | |
| 41 | AXGN | Axogen INC | Stock-Other | 0.92% | — | +7.13% | |
| 42 | IMNM | Immunome INC | Stock-Other | 0.91% | — | +45.24% | |
| 43 | AMLX | Amylyx Pharmaceuticals INC | Stock-Other | 0.89% | — | +62.79% | |
| 44 | IDXX | Idexx Laboratories INC | Stock-Healthcare | 0.87% | +0.87% | NEW | |
| 45 | WAT | Waters CORP | Stock-Healthcare | 0.81% | -0.71% | -36.88% | |
| 46 | ADPT | Adaptive Biotechnologies | Stock-Other | 0.79% | — | +37.36% | |
| 47 | UPB | Upstream Bio INC | Stock-Other | 0.73% | -1.43% | -5.72% | |
| 48 | ERAS | Erasca INC | Stock-Other | 0.68% | +0.68% | NEW | |
| 49 | APGE | Apogee Therapeutics INC | Stock-Other | 0.67% | — | -40.27% | |
| 50 | COO | Cooper Cos Inc/the | Stock-Healthcare | 0.66% | — | -28.29% |
Performance for Q3 2026
+13.1%
Performance Last 4 Quarters
+22.6%
Based on 72% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 90 | $969.6M | 72 | |
| 2025-12-31 | 100 | $1.1B | 59 | |
| 2025-09-30 | 91 | $958.7M | 82 | |
| 2025-06-30 | 88 | $870.1M | 0 | |
| 2025-03-31 | 91 | $843.1M | 100 | |
| 2024-12-31 | 89 | $750.9M | 0 | |
| 2024-09-30 | 93 | $783.4M | 0 | |
| 2024-06-30 | 90 | $746.6M | 0 | |
| 2024-03-31 | 99 | $815.0M | 0 | |
| 2023-12-31 | 89 | $709.9M | 0 | |
| 2023-09-30 | 102 | $545.8M | 0 | |
| 2023-06-30 | 95 | $576.9M | 0 | |
| 2023-03-31 | 83 | $459.8M | 0 | |
| 2022-12-31 | 81 | $375.5M | 0 | |
| 2022-09-30 | 89 | $351.7M | 0 | |
| 2022-06-30 | 76 | $271.5M | 0 | |
| 2022-03-31 | 80 | $341.7M | 0 | |
| 2021-12-31 | 84 | $453.2M | 0 | |
| 2021-09-30 | 74 | $395.3M | 0 | |
| 2021-06-30 | 82 | $457.4M | 97 | |
| 2021-03-31 | 83 | $430.9M | 72 | |
| 2020-12-31 | 83 | $390.3M | 59 | |
| 2020-09-30 | 84 | $377.7M | 49 | |
| 2020-06-30 | 79 | $355.0M | 76 | |
| 2020-03-31 | 66 | $215.8M | 79 | |
| 2019-12-31 | 69 | $346.4M | 0 |
Parkman Healthcare Partners LLC's most significant position changes for 2026-03-31: New buy: Eli Lilly & Co (LLY); Sold out: Masimo CORP (MASI*); Sold out: Terns Pharmaceuticals INC (430); Sold out: Qiagen N.V. (QGEN); Sold out: Amicus Therapeutics INC (AM6).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XENE | Xenon Pharmaceuticals INC | +2.3% | +222.36% | Add |
| 2 | PTCT | Ptc Therapeutics INC | +1.9% | +169.30% | Add |
| 3 | SYK | Stryker CORP | +1.7% | +46.74% | Add |
| 4 | ZBH | Zimmer Biomet Holdings INC | +1.2% | +78.46% | Add |
| 5 | AGIO | Agios Pharmaceuticals INC | +1.2% | +305.13% | Add |
| 6 | ANIP | Ani Pharmaceuticals INC | +1.1% | +93.50% | Add |
| 7 | 4XC1 | Kalvista Pharmaceuticals INC | +1.1% | +3.79% | Add |
| 8 | SNDX | Syndax Pharmaceuticals INC | +1% | +57.05% | Add |
| 9 | BCRX | Biocryst Pharmaceuticals INC | +1% | +89.78% | Add |
| 10 | GPCR | Structure Therapeutics INC | +0.8% | +321.99% | Add |
| 11 | IQV | Iqvia Holdings INC | +0.8% | +146.10% | Add |
| 12 | MLYS | Mineralys Therapeutics INC | -0.4% | -7.34% | Trim |
| 13 | PODD | Insulet CORP | -0.4% | +11.15% | Add |
| 14 | CVS | Cvs Health CORP | -0.5% | -13.97% | Trim |
| 15 | WAT | Waters CORP | -0.7% | -36.88% | Trim |
| 16 | MAZE | Maze Therapeutics INC | -0.7% | -84.78% | Trim |
| 17 | ALNY | Alnylam Pharmaceuticals INC | -0.9% | -43.58% | Trim |
| 18 | VRDN | Viridian Therapeutics INC | -1.2% | -29.20% | Trim |
| 19 | KNSA | Kiniksa Pharmaceuticals International, plc | -1.3% | -61.04% | Trim |
| 20 | UPB | Upstream Bio INC | -1.4% | -5.72% | Trim |
| 21 | BSX | Boston Scientific CORP | -1.6% | -10.34% | Trim |
| 22 | MCK | Mckesson CORP | -1.7% | -65.13% | Trim |
| 23 | LLY | Eli Lilly & Co | — | NEW | New buy |
| 24 | MASI* | Masimo CORP | — | EXIT | Sold out |
| 25 | 430 | Terns Pharmaceuticals INC | — | EXIT | Sold out |
| 26 | QGEN | Qiagen N.V. | — | EXIT | Sold out |
| 27 | AM6 | Amicus Therapeutics INC | — | EXIT | Sold out |
| 28 | QGEN | Qiagen N.V. | — | NEW | New buy |
| 29 | NVST | Envista Holdings CORP | — | NEW | New buy |
| 30 | ABBV | Abbvie INC | — | NEW | New buy |
| 31 | MTD | Mettler-toledo International | — | EXIT | Sold out |
| 32 | A | Agilent Technologies INC | — | EXIT | Sold out |
| 33 | ILMN | Illumina INC | — | NEW | New buy |
| 34 | DHR | Danaher CORP | — | EXIT | Sold out |
| 35 | UNH | Unitedhealth Group INC | — | EXIT | Sold out |
| 36 | IDXX | Idexx Laboratories INC | — | NEW | New buy |
| 37 | ACLXGBX | Arcellx INC | — | EXIT | Sold out |
| 38 | DOCS | Doximity Inc-class A | — | EXIT | Sold out |
| 39 | ERAS | Erasca INC | — | NEW | New buy |
| 40 | BIIB | Biogen INC | — | EXIT | Sold out |
| 41 | DAWNGBX | Day One Biopharmaceuticals I | — | EXIT | Sold out |
| 42 | TNGX | Tango Therapeutics INC | — | NEW | New buy |
| 43 | TMDX | Transmedics Group INC | — | EXIT | Sold out |
| 44 | SDGR | Schrodinger INC | — | EXIT | Sold out |
| 45 | VERA | Vera Therapeutics INC | — | EXIT | Sold out |
| 46 | MRNA | Moderna, Inc. | — | NEW | New buy |
| 47 | IRTC | Irhythm Holdings INC | — | NEW | New buy |
| 48 | MMED | Minimed Group INC | — | NEW | New buy |
| 49 | CARL | Carlsmed INC | — | NEW | New buy |
| 50 | VIR | Vir Biotechnology INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-11 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-12 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-13 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-12 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-13 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-11 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-12 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-13 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-14 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-12 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-13 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-13 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001731437
Total reported value
$969.8M
190 stks
2021-12-31
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001807328
Total reported value
$970.0M
217 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002021208
Total reported value
$970.2M
266 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000035527
Total reported value
$54.7B
4,303 stks
2026-03-31
1 of the top 5 holdings overlap, including Eli Lilly & Co
CIK 0000315032
Total reported value
$126.9B
197 stks
2026-03-31
1 of the top 5 holdings overlap, including Eli Lilly & Co
CIK 0000316011
Total reported value
$84.5B
1 stks
2026-03-31
1 of the top 5 holdings overlap, including Eli Lilly & Co